Possible Protective Effect of Remifentanil Against Testicular Ischemia-Reperfusion Injury

dc.contributor.author Katar, Muzaffer
dc.contributor.author Gevrek, Fikret
dc.contributor.author Fırat, Fatih
dc.contributor.author Unsal, Velıd
dc.contributor.author Tapar, Hakan
dc.contributor.author Karaman, Tugba
dc.contributor.author Kuyucu, Yunus Emre
dc.date.accessioned 2025-02-15T19:35:55Z
dc.date.available 2025-02-15T19:35:55Z
dc.date.issued 2024
dc.description.abstract Objectives: This study aims to evaluate the protective effi- cacy of remifentanil against testicular ischemia-reperfusion injury. Methods: The study included 24 male rats. The rats were randomized into three groups: Group 1 was the control group. Group 2 was subjected to a testicular torsion/ detorsion model. Group 3 underwent similar procedures and additionally received remifentanil (0.6 μg/kg/min) intrave- nously for the first 20 min of reperfusion. Blood samples were taken for biochemical analyses, and orchiectomy was performed for histopathologic examination. Results: Biochemical analysis of blood samples showed a significant increase in antioxidant enzyme activity, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in Group 3 compared to Group 2 (p:0.004 and p:0.002, respectively). There was a dramatic decrease in the levels of proinflammatory cytokines, including interleukin-1 beta (IL-1 Beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in Group 3 compared to Group 2 (p:0.001, p:0.046, and p:0.004, respectively). Similarly, malondialdehyde (MDA) levels decreased in Group 3 compared to Group 2 (p:0.004). Histopathologic examination of Group 3 rats showed positive changes in inflammation, hemorrhage, edema, and conges- tion levels compared to Group 2 (p<0.001). Similarly, there was a positive effect on the Johnsen and Cosentino score in Group 3 compared to Group 2 (p:0.001 and p<0.001, respectively). Conclusions: In our study, it has been documented that remifentanil protects against testicular ischemia-reperfusion injury. en_US
dc.identifier.doi 10.1515/tjb-2024-0111
dc.identifier.issn 1303-829X
dc.identifier.issn 1303-829X
dc.identifier.scopus 2-s2.0-85204802867
dc.identifier.uri https://doi.org/10.1515/tjb-2024-0111
dc.identifier.uri https://search.trdizin.gov.tr/en/yayin/detay/1359382/possible-protective-effect-of-remifentanil-against-testicular-ischemia-reperfusion-injury
dc.language.iso en en_US
dc.publisher Walter de Gruyter GmbH en_US
dc.relation.ispartof Turkish Journal of Biochemistry
dc.relation.ispartof Turkish Journal of Biochemistry-Turk Biyokimya Dergisi en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject Remifentanil en_US
dc.subject Testis en_US
dc.subject Ischemia-Reperfusion Injury en_US
dc.title Possible Protective Effect of Remifentanil Against Testicular Ischemia-Reperfusion Injury en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Kolukçu, Vildan/0000-0002-3914-3899
gdc.author.id Yalcin, Kenan/0000-0003-3560-5862
gdc.author.id Unsal, Velid/0000-0003-1415-0563
gdc.author.id Karaman, Tugba/0000-0002-0724-3326
gdc.author.id Karaman, Serkan/0000-0003-0534-629X
gdc.author.id Katar, Muzaffer/0000-0002-6296-2390
gdc.author.id Gevrek, Fikret/0000-0002-3722-2542
gdc.author.institutional Unsal, Velid
gdc.bip.impulseclass C5
gdc.bip.influenceclass C5
gdc.bip.popularityclass C5
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department Artuklu University en_US
gdc.description.departmenttemp Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Mardin Artuklu Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi,Tokat Gaziosmanpaşa Üniversitesi en_US
gdc.description.endpage 809 en_US
gdc.description.issue 6 en_US
gdc.description.publicationcategory Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q4
gdc.description.startpage 801 en_US
gdc.description.volume 49 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q4
gdc.identifier.openalex W4402557371
gdc.identifier.trdizinid 1359382
gdc.identifier.wos WOS:001314606600001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type TR-Dizin
gdc.oaire.accesstype GOLD
gdc.oaire.diamondjournal false
gdc.oaire.impulse 1.0
gdc.oaire.influence 2.4956475E-9
gdc.oaire.isgreen false
gdc.oaire.keywords Sonstiges
gdc.oaire.keywords ischemia-reperfusion injury
gdc.oaire.keywords 610
gdc.oaire.keywords Naturwissenschaften
gdc.oaire.keywords QD415-436
gdc.oaire.keywords testis
gdc.oaire.keywords Biochemistry
gdc.oaire.keywords remifentanil
gdc.oaire.popularity 3.109071E-9
gdc.oaire.publicfunded false
gdc.openalex.collaboration National
gdc.openalex.fwci 0.90013315
gdc.openalex.normalizedpercentile 0.68
gdc.opencitations.count 0
gdc.plumx.crossrefcites 1
gdc.plumx.mendeley 3
gdc.plumx.newscount 1
gdc.plumx.scopuscites 1
gdc.scopus.citedcount 1
gdc.virtual.author Unsal, Velid
gdc.wos.citedcount 1
relation.isAuthorOfPublication 7c3a66b7-a957-40d9-a628-a536a623b015
relation.isAuthorOfPublication.latestForDiscovery 7c3a66b7-a957-40d9-a628-a536a623b015
relation.isOrgUnitOfPublication cbf35a4a-7e92-4e43-b898-3a77ba9a5cfd
relation.isOrgUnitOfPublication 632fabc5-6bb5-43ef-8a92-8f603b8b9d34
relation.isOrgUnitOfPublication 39ccb12e-5b2b-4b51-b989-14849cf90cae
relation.isOrgUnitOfPublication.latestForDiscovery cbf35a4a-7e92-4e43-b898-3a77ba9a5cfd

Files